Pluri (NASDAQ:PLUR) Releases Earnings Results

Pluri (NASDAQ:PLUR) released its quarterly earnings data on Thursday. The company reported ($0.85) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $0.76 million for the quarter.

Pluri Price Performance

PLUR stock traded down $0.04 on Friday, reaching $1.05. 7,017 shares of the company traded hands, compared to its average volume of 21,905. The firm has a fifty day simple moving average of $1.10 and a 200-day simple moving average of $2.29. Pluri has a one year low of $0.85 and a one year high of $4.29. The company has a market cap of $13.24 million, a P/E ratio of -0.43 and a beta of 0.64.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 26th. One analyst has rated the stock with a Sell rating. According to MarketBeat, Pluri presently has a consensus rating of “Sell”.

Insider Buying and Selling at Pluri

In other news, Director Alexandre Weinstein Manieu purchased 833,334 shares of the company’s stock in a transaction that occurred on Friday, October 23rd. The shares were bought at an average price of $1.50 per share, for a total transaction of $1,250,001.00. Following the purchase, the director directly owned 2,083,334 shares in the company, valued at approximately $3,125,001. This trade represents a 66.67% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 43.16% of the stock is owned by insiders.

Pluri Company Profile

Pluri Inc. is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification. Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.